Display options
Cite
Cattrini C, Castro E, Lozano R, et al. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2019;11(9)doi: 10.3390/cancers11091355.
Cattrini, C., Castro, E., Lozano, R., Zanardi, E., Rubagotti, A., Boccardo, F., & Olmos, D. (2019). Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers, 11(9), . https://doi.org/10.3390/cancers11091355
Cattrini, Carlo, et al. "Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer." Cancers vol. 11,9 (2019). doi: https://doi.org/10.3390/cancers11091355
Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D. Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2019 Sep 12;11(9). doi: 10.3390/cancers11091355. PMID: 31547436; PMCID: PMC6770296.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2019 Sep 12;11(9). doi: 10.3390/cancers11091355.

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

Cancers

Carlo Cattrini, Elena Castro, Rebeca Lozano, Elisa Zanardi, Alessandra Rubagotti, Francesco Boccardo, David Olmos

Affiliations

  1. Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, Italy. [email protected].
  2. Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy. [email protected].
  3. Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain. [email protected].
  4. Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain. [email protected].
  5. CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Malaga, Spain. [email protected].
  6. Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain. [email protected].
  7. CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Malaga, Spain. [email protected].
  8. Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, Italy. [email protected].
  9. Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy. [email protected].
  10. Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, Italy. [email protected].
  11. Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy. [email protected].
  12. Academic Unit of Medical Oncology, IRCCS San Martino Polyclinic Hospital, 16132 Genoa, Italy. [email protected].
  13. Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genoa, Italy. [email protected].
  14. Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain. [email protected].
  15. CNIO-IBIMA Genitourinary Cancer Unit, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Malaga, Spain. [email protected].

PMID: 31547436 PMCID: PMC6770296 DOI: 10.3390/cancers11091355

Abstract

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient's risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers.

Keywords: abiraterone acetate; apalutamide; docetaxel; enzalutamide; hormone-naïve prostate cancer; hormone-sensitive prostate cancer; radiotherapy

References

  1. J Clin Oncol. 2018 Feb 10;36(5):446-453 - PubMed
  2. Clin Cancer Res. 2019 Feb 1;25(3):928-936 - PubMed
  3. Lancet. 2000 Apr 29;355(9214):1491-8 - PubMed
  4. Prostate. 2018 Sep;78(12):889-895 - PubMed
  5. Eur Urol Oncol. 2019 Jan 30;:null - PubMed
  6. Eur Urol. 2016 Dec;70(6):906-908 - PubMed
  7. Nat Med. 2016 Apr;22(4):369-78 - PubMed
  8. Semin Nucl Med. 2019 Jul;49(4):302-312 - PubMed
  9. Lancet. 2011 Mar 5;377(9768):813-22 - PubMed
  10. J Clin Oncol. 2018 Apr 10;36(11):1080-1087 - PubMed
  11. N Engl J Med. 2019 Jul 11;381(2):121-131 - PubMed
  12. Crit Rev Oncol Hematol. 2017 Oct;118:42-53 - PubMed
  13. N Engl J Med. 2018 Jun 28;378(26):2465-2474 - PubMed
  14. N Engl J Med. 2018 Feb 15;378(7):645-657 - PubMed
  15. Urology. 2017 Aug;106:146-152 - PubMed
  16. Eur Urol. 2017 Jul;72(1):14-19 - PubMed
  17. Ther Adv Med Oncol. 2017 Aug;9(8):565-573 - PubMed
  18. Eur Urol. 2019 Jan;75(1):111-128 - PubMed
  19. J Urol. 2002 Jul;168(1):9-12 - PubMed
  20. Cell. 2018 Jun 14;173(7):1770-1782.e14 - PubMed
  21. Lancet Oncol. 2009 Sep;10(9):872-6 - PubMed
  22. Eur Urol. 2015 Aug;68(2):205-6 - PubMed
  23. Eur Urol. 2017 Jul;72(1):118-124 - PubMed
  24. J Clin Oncol. 2018 May 10;36(14):1389-1395 - PubMed
  25. J Clin Oncol. 2019 Feb 20;37(6):490-503 - PubMed
  26. J Clin Oncol. 2019 May 1;37(13):1120-1129 - PubMed
  27. Eur Urol. 2015 Aug;68(2):196-204 - PubMed
  28. Br J Cancer. 2014 Mar 18;110(6):1655-62 - PubMed
  29. Eur Urol. 2018 Jun;73(6):847-855 - PubMed
  30. BJU Int. 2004 Jun;93(9):1177-82 - PubMed
  31. BJU Int. 2018 May;121(5):680-683 - PubMed
  32. N Engl J Med. 2019 Jul 4;381(1):13-24 - PubMed
  33. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436 - PubMed
  34. J Natl Cancer Inst. 2003 Sep 3;95(17):1300-11 - PubMed
  35. JAMA Oncol. 2016 Dec 1;2(12):1598-1606 - PubMed
  36. N Engl J Med. 2014 Jul 31;371(5):424-33 - PubMed
  37. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed
  38. N Engl J Med. 1998 Oct 8;339(15):1036-42 - PubMed
  39. Ann Oncol. 2018 May 1;29(5):1235-1248 - PubMed
  40. JAMA Oncol. 2018 May 1;4(5):702-706 - PubMed
  41. N Engl J Med. 2017 Jul 27;377(4):338-351 - PubMed
  42. Lancet Oncol. 2019 May;20(5):686-700 - PubMed
  43. J Urol. 2015 Aug;194(2):378-85 - PubMed
  44. Eur Urol. 2019 Aug 22;:null - PubMed
  45. Cancer. 2019 Feb 1;125(3):340-352 - PubMed
  46. Eur Urol Focus. 2017 Dec;3(6):646-649 - PubMed
  47. N Engl J Med. 2018 Apr 12;378(15):1408-1418 - PubMed
  48. Eur Urol. 2014 Nov;66(5):799-802 - PubMed
  49. Ann Oncol. 2018 May 1;29(5):1249-1257 - PubMed
  50. Eur J Cancer. 2018 Nov;103:78-87 - PubMed
  51. Lancet. 2018 Dec 1;392(10162):2353-2366 - PubMed
  52. Eur Urol. 2019 Mar;75(3):410-418 - PubMed
  53. Am J Surg Pathol. 2016 Feb;40(2):244-52 - PubMed
  54. J Clin Oncol. 2019 Jul 22;:JCO1900799 - PubMed
  55. N Engl J Med. 2004 Oct 7;351(15):1502-12 - PubMed
  56. Lancet Oncol. 2018 Feb;19(2):194-206 - PubMed
  57. J Clin Oncol. 2016 Jan 20;34(3):280-5 - PubMed
  58. Eur Urol. 2016 Jun;69(6):992-5 - PubMed
  59. N Engl J Med. 2015 Aug 20;373(8):737-46 - PubMed
  60. JAMA Oncol. 2019 Apr 1;5(4):471-478 - PubMed
  61. J Urol. 2003 Jan;169(1):164-9 - PubMed
  62. Lancet. 2016 Mar 19;387(10024):1163-77 - PubMed
  63. Lancet Oncol. 2016 Feb;17(2):243-256 - PubMed
  64. J Natl Cancer Inst. 2004 Jun 2;96(11):879-82 - PubMed
  65. Eur Urol Focus. 2019 Mar;5(2):159-161 - PubMed
  66. N Engl J Med. 2012 Sep 27;367(13):1187-97 - PubMed
  67. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  68. N Engl J Med. 2019 Mar 28;380(13):1235-1246 - PubMed
  69. N Engl J Med. 2015 Oct 29;373(18):1697-708 - PubMed
  70. J Clin Oncol. 2018 Apr 10;36(11):1088-1095 - PubMed
  71. Eur Urol. 2019 Apr;75(4):667-675 - PubMed
  72. N Engl J Med. 2017 Jul 27;377(4):352-360 - PubMed
  73. Eur Urol. 2016 Aug;70(2):256-62 - PubMed
  74. J Clin Oncol. 2018 Aug 1;36(22):2350 - PubMed
  75. J Clin Oncol. 2017 Jul 1;35(19):2149-2156 - PubMed
  76. Clin Cancer Res. 2018 Nov 15;24(22):5585-5593 - PubMed
  77. Lancet Oncol. 2013 Feb;14(2):149-58 - PubMed
  78. J Clin Oncol. 2014 Apr 10;32(11):1143-50 - PubMed

Publication Types